METAGENOMI THERAPEUTICS INC

Metagenomi Therapeutics (MGX) slides 27% as thin liquidity and broken 200‑day SMA raise doubts over its IPO prospects—investors urge caution.

MGX’s new partnership with a leading biopharma could spark a turnaround, but hidden costs and weak fundamentals mean investors should stay cautious.

Metagenomi Therapeutics (MGX) saw a 3.57% rise to $0.83, outpacing peers like ELWT and STRR, amid a 52‑week low at $0.77 and $30.7M cap.